BRIEF published on 02/28/2025 at 07:35, 1 year 8 months ago ABIONYX strengthens its commitment against LCAT Deficiency Rare Disease Marketing Authorization LCAT Deficiency Biomedicine Norum Disease
PRESS RELEASE published on 02/28/2025 at 07:30, 1 year 8 months ago Informations privilégiées / Autres communiqués ABIONYX s’engage dans la Déficience LCAT (Maladie de Norum) en soutenant les patients et préparant l'AMM, bénéficiant de la Désignation de Maladie Orpheline en Europe et aux USA ABIONYX EMA Déficience LCAT Maladie De Norum Désignation Orpheline
PRESS RELEASE published on 02/28/2025 at 07:30, 1 year 8 months ago Inside Information / Other news releases ABIONYX renews commitment to treat LCAT Deficiency (Norum's disease) and provides updates on advances, including submission of Marketing Authorization Application and Orphan Disease Designation ABIONYX LCAT Deficiency Rare Disease Day Marketing Authorization Application Orphan Disease Designation
BRIEF published on 02/27/2025 at 19:25, 1 year 8 months ago ABIONYX Pharma Reports Stable Revenue and Cash Position for 2024 2024 Financial Results Innovative Therapies ABIONYX Pharma Compassionate Access CRO Industry
BRIEF published on 02/27/2025 at 19:25, 1 year 8 months ago ABIONYX Pharma annonce un chiffre d'affaires et une situation de trésorerie stables pour 2024 Résultats Financiers 2024 ABIONYX Pharma Thérapies Innovantes Accès Compassionnel Industrie Des CRO
PRESS RELEASE published on 02/27/2025 at 19:20, 1 year 8 months ago Inside Information / Information on annual revenues ABIONYX Pharma reports €4.6m revenue and €3.2m cash at the end of Q4 2024. Details on business activities and financial performance included Revenue Cash Position Financial Update Biopharma ABIONYX Pharma
PRESS RELEASE published on 02/27/2025 at 19:20, 1 year 8 months ago Informations privilégiées / Information sur chiffre d’affaires annuel ABIONYX Pharma annonce un chiffre d'affaires consolidé de 4,6M€ et une trésorerie de 3,2M€ au 31 décembre 2024 Chiffre D'affaires Trésorerie Biopharma ABIONYX Pharma Thérapies Innovantes
BRIEF published on 02/20/2025 at 07:35, 1 year 8 months ago ABIONYX Pharma reçoit un soutien de 8,7 millions d'euros pour son projet sur le sepsis France 2030 ABIONYX Pharma Sepsis Soutien Financier Biomédicament
BRIEF published on 02/20/2025 at 07:35, 1 year 8 months ago ABIONYX Pharma receives €8.7 million in support for its sepsis project Financial Support France 2030 ABIONYX Pharma Sepsis Biomedicine
PRESS RELEASE published on 02/20/2025 at 07:30, 1 year 8 months ago Informations privilégiées / Autres communiqués ABIONYX Pharma reçoit 8,7 M€ de soutien de l’Etat pour combattre le sepsis, 3ème cause de décès mondiale, grâce à son biomédicament CER-001 France 2030 ABIONYX Pharma Sepsis Soutien Financier Biomédicament
Published on 11/12/2026 at 15:55, 51 minutes ago DIAGENS Leads in Two Major Global AI Benchmarks and Extends Chest and Abdominal CT Analysis to 509 Imaging Targets, Ushering in a New Era for Medical Imaging AI
Published on 11/12/2026 at 14:31, 2 hours 15 minutes ago First Breach Inc. Announces Third Quarter 2026 Earnings Conference Call
Published on 11/12/2026 at 14:00, 2 hours 46 minutes ago GameSquare Announces Peaky Blinders Digital Fan Experience, Advancing the Company's IP Monetization Strategy
Published on 11/12/2026 at 14:00, 2 hours 46 minutes ago NuRAN Wireless Highlights Recurring Revenue Economics and Growth Potential of Its 5,092-Tower Contracted NaaS Portfolio
Published on 11/12/2026 at 13:45, 3 hours 1 minute ago Amarc and Freeport Successfully Complete 2026 Joy Copper-Gold District Exploration Program
Published on 11/12/2026 at 16:29, 16 minutes ago Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014: Purchase of own shares – final notice
Published on 11/12/2026 at 16:06, 40 minutes ago Leadership change at GEA: Klaus Stojentin to succeed Stefan Klebert as CEO
Published on 11/12/2026 at 16:05, 40 minutes ago Cision Introduces AI-Powered Cision Intelligence to Help Brands See More and Act with Confidence
Published on 11/12/2026 at 16:05, 41 minutes ago EQS-Adhoc: GEA Group Aktiengesellschaft: Stefan Klebert to leave the Executive Board of GEA Group Aktiengesellschaft after the 2027 Annual General Meeting; his successor will be Klaus Stojentin
Published on 11/12/2026 at 08:56, 7 hours 49 minutes ago Number of shares and voting rights - October 2026 (In French only)
Published on 11/12/2026 at 08:56, 7 hours 49 minutes ago Nombre total d'actions et droits de vote - octobre 2026
Published on 11/12/2026 at 08:40, 8 hours 6 minutes ago FREY forms a €400 million equity partnership with GIC to invest in premium European retail parks
Published on 11/12/2026 at 08:40, 8 hours 6 minutes ago FREY et GIC s’associent pour investir 400 M€ de capital dans les retail parks premium en Europe
Published on 11/10/2026 at 18:00, 1 day 22 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
